Praxis Precision Medicines (PRAX) AI Stock Analysis

• Market Cap: $875.87M
• Dividend Yield: N/A
• Average Volume (3M): 282.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 270.02%
• EPS Growth: 32.69%
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -3.29
• Shares Outstanding: 20,368,982
• 10 Day Avg. Volume: 257,804
• 30 Day Avg. Volume: 282,488
• PEG Ratio: -0.09
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.27
• Enterprise Value/Market Cap: >-0.01
• Enterprise Value/Revenue: -0.04
• Enterprise Value/Gross Profit: -0.10
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $111.13
• Price Target Upside: 158.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 53 Neutral
• Price Target: $44.00 ▲(2.33%Upside)

Praxis Precision Medicines faces significant financial performance challenges, with ongoing losses and negative cash flows being the most impactful factors. Despite these hurdles, promising corporate developments and technical indicators offer some optimism. However, the negative P/E ratio and lack of dividend yield further underscore the need for caution in valuation.

Positive Factors

Drug Development

The company's drug development engine could continue to add new products to the pipeline, reinforcing its potential in the market.

Pipeline Strength

Praxis has the most impressive pipeline in epilepsy across DEEs, FOS, and generalized seizures.

Study Results

Investor feedback suggests that successful results in the study could lead to a positive stock move of 20% or more.

Negative Factors

Study Risks

There is a 10% likelihood that the drug's efficacy may not be competitive, which could result in a 40% decrease in stock value.

Trial Failure

The lead asset ulixacaltamide recently failed the interim analysis of the Phase 3 essential tremor program.

Praxis Precision Medicines Business Overview & Revenue Model

Company Description

Praxis Precision Medicines (PRAX) is a biotechnology company focused on developing therapies for patients with central nervous system (CNS) disorders. The company leverages its deep understanding of genetic insights to identify novel targets and develop highly selective therapies. Praxis aims to address the unmet needs in CNS diseases by developing a robust pipeline of product candidates utilizing precision medicine approaches.

How the Company Makes Money

Praxis Precision Medicines primarily generates revenue through the development and commercialization of its pipeline of CNS disorder therapies. The company invests in research and development to advance its drug candidates through clinical trials, seeking regulatory approval to bring these therapies to market. Revenue is expected to be generated from product sales, once these therapies are approved, as well as through potential partnerships and collaborations with other pharmaceutical companies. Praxis may also receive milestone payments and royalties from licensing agreements with partners who wish to commercialize its therapies in specific markets.

Praxis Precision Medicines Financial Statement Overview

Summary

Praxis Precision Medicines is experiencing significant financial challenges, characterized by substantial net losses and negative cash flows. Despite a strong gross profit margin and low debt levels, the company's operational inefficiencies and declining revenue growth are major concerns. The balance sheet remains stable, but the negative return on equity and worsening free cash flow highlight the need for a strategic reevaluation to improve financial health.

Income Statement

Praxis Precision Medicines shows a declining financial performance. The gross profit margin is relatively high at 98.1% for TTM (Trailing-Twelve-Months), but the company is suffering from significant net losses with a net profit margin of -2617.6%. Revenue has decreased by 5% in the TTM period compared to the previous annual report. Both EBIT and EBITDA margins are deeply negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a relatively stable financial position with a debt-to-equity ratio of 0.0024, indicating low leverage. However, the return on equity is significantly negative at -48.4% due to ongoing losses. The equity ratio stands at 91.8%, suggesting strong equity financing but persistent operational losses are a concern.

Cash Flow

Cash flow analysis highlights ongoing financial challenges. The free cash flow is negative and has worsened by 24.5% compared to the previous year. Operating cash flow to net income ratio is 0.77, indicating cash flow issues. The free cash flow to net income ratio is 0.77, reflecting insufficient cash flow to cover losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.12M	8.55M	2.45M	0.00	0.00	0.00
Gross Profit	7.97M	8.20M	2.45M	-1.17M	-1.59M	-746.00K
EBITDA	-232.71M	-199.81M	-125.94M	-212.86M	-165.47M	-61.08M
Net Income	-212.56M	-182.82M	-123.28M	-213.07M	-166.88M	-61.82M
Balance Sheet
Total Assets	478.74M	483.11M	87.95M	115.13M	292.75M	303.18M
Cash, Cash Equivalents and Short-Term Investments	327.99M	392.57M	81.30M	100.49M	275.91M	296.61M
Total Debt	1.07M	1.37M	2.50M	4.50M	4.31M	763.00K
Total Liabilities	39.52M	37.66M	18.28M	39.02M	41.94M	15.72M
Stockholders Equity	439.21M	445.45M	69.67M	76.11M	250.81M	287.46M
Cash Flow
Free Cash Flow	-163.85M	-131.76M	-111.19M	-185.49M	-125.60M	-52.62M
Operating Cash Flow	-163.91M	-131.76M	-111.14M	-185.04M	-124.55M	-52.62M
Investing Cash Flow	-208.34M	-248.49M	38.95M	96.89M	-140.52M	4.00K
Financing Cash Flow	385.83M	514.32M	91.87M	10.46M	107.59M	304.42M

Praxis Precision Medicines Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 43.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRAX, the sentiment is Negative. The current price of 43 is below the 20-day moving average (MA) of 43.03, above the 50-day MA of 39.43, and below the 200-day MA of 57.90, indicating a neutral trend. The MACD of 1.12 indicates Positive momentum. The RSI at 54.40 is Neutral, neither overbought nor oversold. The STOCH value of 54.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRAX.

Praxis Precision Medicines Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	54 Neutral	$752.73M	―	222.83%	―	29.88%	35.11%
PRAX	53 Neutral	$875.87M	―	-63.56%	―	270.02%	32.69%
GYRE	52 Neutral	$670.20M	154.91	11.62%	―	―	―
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
NTLA	50 Neutral	$990.26M	―	-57.92%	―	-13.37%	2.57%
XNCR	46 Neutral	$579.33M	―	-33.48%	―	-25.88%	-29.16%
NUVB	45 Neutral	$656.71M	―	-119.66%	―	―	-551.08%

Praxis Precision Medicines Corporate Events

Praxis Precision Medicines Holds Annual Stockholders Meeting

On June 26, 2025, Praxis Precision Medicines, Inc. held its Annual Meeting of Stockholders, where key decisions were made. Stockholders elected two Class II directors, ratified the appointment of Ernst & Young LLP as the independent accounting firm, and approved executive compensation on a non-binding basis. These outcomes reflect the company’s ongoing governance and operational strategies, potentially impacting its future direction and stakeholder relations.

The most recent analyst rating on (PRAX) stock is a Buy with a $114.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.

Praxis Precision Medicines Shares Promising EMBOLD Study Data

On May 2, 2025, Praxis Precision Medicines updated its corporate presentation and provided significant updates on its developmental programs at an investor event. Notably, the company shared promising data from the EMBOLD study, showing sustained seizure reduction in patients with SCN2A and SCN8A DEEs treated with relutrigine. Additionally, Praxis announced the trial design for the EMERALD study, a Phase 3 clinical trial evaluating relutrigine in a broader DEE patient population. The company also plans to nominate a development candidate for its PRAX-100 program targeting SCN2A loss-of-function mutations by mid-2025. These updates reflect Praxis’s ongoing efforts to advance its pipeline and strengthen its position in the CNS disorder treatment market.